Literature DB >> 17338933

The nitric oxide/cGMP signaling pathway in pulmonary hypertension.

James R Klinger1.   

Abstract

This article briefly reviews the background of endothelium-dependent vasorelaxation, describes the nitric oxide/cGMP/protein kinase pathway and its role in modulating pulmonary vascular tone and remodeling, and describes three approaches that target the nitric oxide/cGMP pathway in the treatment of patients with pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338933     DOI: 10.1016/j.ccm.2006.12.002

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  23 in total

Review 1.  Review of inhaled nitric oxide in the pediatric cardiac surgery setting.

Authors:  Paul A Checchia; Ronald A Bronicki; Brahm Goldstein
Journal:  Pediatr Cardiol       Date:  2012-04       Impact factor: 1.655

Review 2.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

3.  Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Zeling Cao; Stephen C Mathai; Laura K Hummers; Ami A Shah; Fredrick M Wigley; Noah Lechtzin; Paul M Hassoun; Reda E Girgis
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

4.  Heterogeneity of pulmonary endothelial cyclic nucleotide response to Pseudomonas aeruginosa ExoY infection.

Authors:  K A Morrow; R Seifert; V Kaever; A L Britain; S L Sayner; C D Ochoa; E A Cioffi; D W Frank; T C Rich; T Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-18       Impact factor: 5.464

5.  Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.

Authors:  Peter M Mourani; Marci K Sontag; D Dunbar Ivy; Steven H Abman
Journal:  J Pediatr       Date:  2008-10-31       Impact factor: 4.406

Review 6.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

7.  Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging.

Authors:  Jason Lee; Reuben Reich; Fang Xu; Pravin B Sehgal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-31       Impact factor: 5.464

Review 8.  Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Authors:  John S Kim; Julia McSweeney; Joanne Lee; Dunbar Ivy
Journal:  Pediatr Crit Care Med       Date:  2016-03       Impact factor: 3.624

Review 9.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

10.  Nitric oxide synthases in infants and children with pulmonary hypertension and congenital heart disease.

Authors:  Thomas Hoehn; Brigitte Stiller; Allan R McPhaden; Roger M Wadsworth
Journal:  Respir Res       Date:  2009-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.